Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + Olodaterol in COPD (Torracto)
NCT01525615Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2012
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Adjusted Mean Endurance Time During Constant Work Rate Cycle Ergometry at 12 weeks. Started Feb 2012; status: completed.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01525615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01525615.